BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Augmenix Closes $6.1 Million Financing


10/19/2009 7:03:38 AM

Bookmark and Share

WALTHAM, Mass., Oct. 16 /PRNewswire/ -- Augmenix announced today that it has closed a $6.1 million Series B financing. The round was led by Ascension Health Ventures (AHV) in St. Louis, Mo., with continued participation by existing investors, Versant Ventures and Pinnacle Ventures. Also participating were Catalyst Health Ventures and several private investors.

"The field of radiation oncology has traditionally been of a large capital equipment mindset in solving problems. Augmenix plans to bring novel biomaterials technology into this field to create absorbable devices that will have a huge impact on how clinicians are able to improve targeting of radiotherapy while minimizing radiation damage to organs at risk," commented Amar Sawhney, Augmenix President and CEO.

The proceeds will be used to conduct the clinical and commercial development of the SpaceOAR((TM)). System in Europe and the United States, as well as to develop other products in the Augmenix pipeline.

"We are excited about working with Augmenix to meet significant medical needs in radiation oncology and urology. We have worked with Amar and his team before and like the technology, as well as the rapid and cost-effective execution model embraced by Augmenix," said Tara Butler, Investment Director, AHV, who will join the company's Board of Directors.

About Augmenix, Inc.:

Augmenix, Inc. is a privately held company based in Waltham, Mass., focused on the development and commercialization of implantable biomaterial based solutions for improved radiotherapy safety and/or efficacy. Augmenix's first product, SpaceOAR system is an injectable tissue spacer that will decrease rectal morbidity or enable improved efficacy in prostate radiotherapy. The company was founded in 2008.

About Ascension Health Ventures:

Ascension Health Ventures (www.ascensionhealthventures.org) was launched in 2001 as a wholly-owned subsidiary of Ascension Health. AHV's role has been to construct and manage a strategic portfolio of investments that deliver a venture investment return, have the potential to transform the healthcare industry and significantly enhance the quality of patient care. CHV II, LP, a limited partnership between Ascension Health, Catholic Health Initiatives, Catholic Health East and Catholic Healthcare West, has been formed to expand this strategic investment initiative to other Catholic healthcare systems. AHV is the general partner of CHV II, LP.


Augmenix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES